Cyclerion Therapeutics

CYCN71

Penny Stock

$2.81arrow_drop_down4.09%-$0.12

Penny Stock

CYCN71

$2.81

arrow_drop_down4.09%-$0.12

Penny Stock

Performance History

Key Stats
Open	$3.00
Prev. Close	$3.00
EPS	-4.29
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$7.29M
PE Ratio	-

	LOW	HIGH
Day Range	2.85	3.02
52 Week Range	1.75	5.25

Ratios

Revenue	-



EBITDA Margin %	-

EPS	-4.29

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Cyclerion Therapeutics (CYCN)

Cyclerion Therapeutics Inc (CYCN) is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative treatments for serious and rare diseases. The company's mission is to improve the lives of patients by leveraging its expertise in the field of soluble guanylate cyclase (sGC) pharmacology. sGC is an important enzyme involved in multiple biological signaling pathways, and dysregulation of sGC has been implicated in a variety of diseases.

Cyclerion's lead product candidate is CY6463, a highly selective sGC stimulator that is being evaluated for the treatment of several diseases, including sickle cell disease, diabetic nephropathy, and heart failure with preserved ejection fraction (HFpEF). CY6463 has shown promising results in early clinical trials, demonstrating potential benefits in terms of improving vascular function and reducing inflammation.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Dr. Peter M. Hecht Ph.D.
Headquarters: Cambridge
Employees: 16
Exchange: NASDAQ

Keep an eye on Cyclerion Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is the market capitalization of Cyclerion Therapeutics (CYCN)?

Cyclerion Therapeutics (CYCN) has a market capitalization of $7.37M. The average daily trading volume is 2.62K, indicating the stock's liquidity and investor engagement.

help

What is Cyclerion Therapeutics 's (CYCN) price per share?

The current price per share for Cyclerion Therapeutics (CYCN) is $2.81. The stock has seen a price change of -$0.12 recently, indicating a -4.1% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Cyclerion Therapeutics (CYCN)?

For Cyclerion Therapeutics (CYCN), the 52-week high is $5.25, which is 86.83% from the current price. The 52-week low is $1.75, the current price is 60.57% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Cyclerion Therapeutics (CYCN) a growth stock?

Cyclerion Therapeutics (CYCN) has shown an average price growth of 0.41% over the past three years. It has received a score of 98 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Cyclerion Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Cyclerion Therapeutics (CYCN) stock price performance year to date (YTD)?

As of the latest data, Cyclerion Therapeutics (CYCN) has a year-to-date price change of -19.71%. Over the past month, the stock has experienced a price change of 8.08%. Over the last three months, the change has been 0.79%. Over the past six months, the figure is -12.19%. Looking at a longer horizon, the five-year price change stands at -98.99%.

help

Is Cyclerion Therapeutics (CYCN) a profitable company?

Cyclerion Therapeutics (CYCN) has a net income of -$5.26M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$9.65M. Furthermore, the EBITDA is $0.